

**CURRICULUM VITAE**  
**SUNIL S. PATEL M.D., Ph.D.**  
January 2012

**Personal Information**

Date of Birth: December 26, 1961  
Place of Birth: Palasar, India  
Citizenship: USA  
Age: 50  
Home Address: 4224 South 20<sup>th</sup> Street  
Abilene, Texas 79605  
Home Telephone: (325) 793-2348  
Family: Wife: Laurie McAnally, MD (Family Practice)  
Children: Rajal Patel  
Jayna Patel  
Vijay Patel

Business Address: Ophthalmology Specialists of Texas, PA  
5441 Health Center Drive  
Abilene, Texas 79606  
Business Telephone: (325) 673-9806  
Cellular Telephone: (325) 660-8984  
Fax number: (325) 673-9809

**Current Employment**

Staff Vitreoretinal Surgeon  
Managing Partner  
Ophthalmology Specialists of Texas, PA  
West Texas Retina Consultants  
5441 Health Center Drive  
Abilene, Texas 79606  
(325) 673-9806

President  
Integrated Clinical Research, LLC  
Retina Research Institute of Texas  
5441 Health Center Drive  
Abilene, Texas 79606  
(325) 690-4414

President  
Abilene Surgery Center, LLC  
5601 Health Center Drive  
Abilene, Texas 79606  
(325) 690-4466  
Assistant Clinical Professor  
Department of Ophthalmology  
Texas Tech University School of Medicine  
Lubbock, Texas

## **Previous Employment**

Vitreoretinal Surgeon – Texas Retina Associates, PA (9/1997 to 9/2000), Dallas, Texas

Clinical Instructor – Doheny Eye Institute (7/1996 to 8/1997), University of Southern California, Los Angeles, California

## **Current or Previous Consulting Experience**

Allergan  
Alcon  
EyeTech  
Genentech  
Ophthotech

## **Education**

Bachelor of Science: University of California, Los Angeles (UCLA),  
(Biochemistry) Los Angeles, California (9/1979-6/1983)

Doctor of Philosophy: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, Texas (6/1985-8/1989) (Immunology)

Doctor of Medicine: University of Texas Southwestern Medical School, Dallas, Texas (7/1983 - 5/1991)

## **Doctor of Philosophy Thesis**

Advisor: Peter E. Lipsky, MD (6/1985-8/1989)  
Date of defense: 8/21/1989  
Title: Functional and phenotypic analysis of human T cell clones

## **Internship**

Presbyterian Hospital of Dallas (7/1991-6/1992), Dallas, Texas.

## **Residency**

Ophthalmology: Doheny Eye Institute-Los Angeles County Hospital (7/1992-6/1995), University of Southern California, Los Angeles, California.

## **Fellowships**

Surgical and medical vitreoretinal fellowship: Doheny Eye Institute-Los Angeles County Hospital (7/1/95 to 6/30/96), University of Southern California, Los Angeles, California.

Uveitis fellowship: Doheny Eye Institute-Los Angeles County Hospital (7/1/96 to 7/31/97), University of Southern California, Los Angeles, California.

## **Additional Training**

Director of the vitreoretinal service at the USC-Los Angeles County Hospital (7/1/96 to 7/31/97).

Chief Resident at USC-Los Angeles County Hospital (7/1/96 to 6/30/97).

Collaborative Ocular Melanoma Study (COMS) certification for the diagnosis and management of choroidal melanoma (7/1/96 to 8/1/97).

Ocular Oncology Training – Lynn Murphree at Doheny Eye Institute – USC School of Medicine (7/1/95 to 6/30/96)

SOCA (Study for Ocular Complications of AIDS) certification for the surgical placement of intraocular ganciclovir implant.

Investigator Education for the Protection of Human Research Subjects (December 04, 2003)

## **Medical License**

California: A051774

Texas: K4185

DEA: BP3670329

DPS: H0104495

## **Ophthalmology Board Certification**

Diplomate of the American Board of Ophthalmology (10/1996)

Diplomate of the American Board of Ophthalmology (Renewal 10/2006)

## **Professional Societies**

American Academy of Ophthalmology

American Society of Retinal Specialists

American Uveitis Society

American Medical Association

American Association of Immunologists

American Association for the Advancement of Science

Association for Research in Vision and Ophthalmology

International Society for Stem Cell Research

International Society for Cellular Therapy

Alpha Omega Alpha National Medical Honor Society

Phi Beta Kappa

Texas Ophthalmological Association

## **Undergraduate Awards, Honors, and Fellowships**

Dean's Honor List at UCLA

Marilyn F. Lohr Memorial Physics Scholarship

Departmental Honors in the Department of Chemistry and Biochemistry at UCLA

Magna Cum Laude

Phi Beta Kappa National Honor Society

Golden Key Honor Society

UCLA Summer Research Fellowship

American Heart Association Research Fellowship

## Graduate Awards, Honors, and Fellowships

Southwestern Medical Foundation Scholarship  
 Medical Scientist Training Program (National Institutes of Health) MD/PHD Predoctoral Fellowship  
 Harold C. Simmons Research Fellowship  
 Alpha Omega Alpha Medical Honor Society

## Post-Graduate Honors and Awards

Award for Excellence in Resident Training at the Doheny Eye Institute (1997)  
 American Academy of Ophthalmology Achievement Award (2009)  
 Texas Ophthalmological Association Council Member (2004-2010)  
 Texas Ophthalmological Association President Elect (2011)  
 Scientific Reviewer for *Ophthalmology*.

## Research Interests

Cellular therapy in the management of retinal degenerative diseases.  
 Molecular mechanisms of immune regulation.  
 Applications of novel molecules in the management of retinal degenerative diseases.  
 Translational research – applications of regenerative medicine for retinal degenerative diseases.  
 New and innovative surgical therapies for management of retinal diseases.

## Clinical Research Studies:

**Alimera FAME C-01-11-008**, “An Open Label, Multi-center Extension Study of the Safety and Utility of the New Inserter of Iluvien® (Fluocinolone Acetonide Intravitreal Insert) 0.19mg and the Safety of Iluvien in subjects with Diabetic Macular Edema” (2011-Present)  
 Primary Investigator: Sunil S. Patel M.D., PhD  
 Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Allergan REACH AGN-150998**, “Single and Repeat Dose of the Safety and Efficacy of AGN-150998 in patients with Exudative Age-related Macular Degeneration” (2011-Present)  
 Primary Investigator: Sunil S. Patel M.D., PhD  
 Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Lpath NEXUS LT1009-Oph-003**, “A phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSonop™ (Sonepcizumab [LT1009]) As either Monotherapy or adjunctive Therapy to Lucentis® or Avastin® Alone for the treatment of subjects with choroidal Neovascularization Secondary to Age-Related Macular Degeneration” (2011-Present)  
 Primary Investigator: Sunil S. Patel M.D., PhD  
 Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Regeneron Vista VGFT-OD-1009**, “A Double-Masked, Randomized, Active-Controlled, Phase III Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema” (2011-Present)  
 Primary Investigator: Grant P. Janzen, M.D.  
 Sub-Investigator: S. Young Lee, M.D., Sunil S. Patel M.D., PhD

**Allergan BDP 208397-001**, “A 12-Month, Multicenter, 2-Stage (Open Label, Dose-Escalation, Followed by Masked, Randomized) Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients with Macular Edema (ME) Associated with Retinal Vein Occlusion (RVO)” (2011-Present)  
 Primary Investigator: Sunil S. Patel M.D., PhD  
 Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**GlaskoSmithKline BAM114341**, “A Phase II, Multi-centre, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study to investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)” (2011- Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Lpath Incorporated LT1009-OPH002**, “A Phase 1B Multicenter, Open-Label and Randomized study of ISONEP (Sonopizumab/LT1009) administered as Intravenous Injections to subjects with PED Secondary to Exudative Age-Related Macular Degeneration or Polypoidal Choroidal Vasculopathy.” (2011-Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Genentech Shore FVF4967g**, “A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab in Subjects with Macular Edema Following Retinal Vein Occlusion.” (2011-Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Genentech Mahalo CFD4870g**, “A Phase Ib/II, Multicenter, Randomized, Single Masked, Sham-Injection-Controlled study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered monthly or Every other month to patients with Geographical Atrophy.” (2010-Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub- Investigator: S.Young Lee, M.D., Grant P. Janzen, M.D.

**Pfizer B1181002**, “A Phase I, Double-masked, Placebo-controlled study evaluating the Safety and Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Dosages of RN6G (PF-04382923) in subjects with Advanced Dry, Age-Related Macular Degeneration (AMD) including Geographical Atrophy” (2010-Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Allergan 190342-033D**, “A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System.” (2010-Present)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S.Young Lee, M.D., Grant P. Janzen, M.D.

**DRCR Protocol N**, “An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy.” (2010-Current)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Ophthotech OPH1001**, “A PHASE 2, Randomized, Double-Masked, Controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in combination with Lucentis® in subjects with Neovascular Age-Related Macular Degeneration” (2010-Current)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Regeneron VGFT-OD-0819**, "A Randomized, Double Masked, Controlled Phase III Study of the efficacy, safety and tolerability of repeated intravitreal administration of VEGF-Trap in subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). (2009-Present)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Genentech FVF4579g Harbor**, “A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the efficacy and safety of 0.5mg and 2.0 mg Ranibizumab administered monthly or an as-needed basis (PRN) in patients with Subfoveal Neovascular Age-related Macular Degeneration. (2009 – Present)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Alcon C-08-36 (GATE)**, “The safety and efficacy of AL-8309B ophthalmic Solution for the treatment of Geographical Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). (2009-Present)

Sub-Investigator: Sunil S. Patel M.D., Ph.D. Primary Investigator: S. Young Lee, M.D.

**Genentech FVF4168g RIDE**, “A phase III, double-masked, multicenter, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus.” (2007-Current)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator, S. Young Lee, M.D., Grant P. Janzen, M.D.

**DRCR Protocol O**, “Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema.” (2009-2011)

Principal Investigator: Sunil S. Patel M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Ophthotech OPH3000ss**, “A phase I ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetics profile of multiple intravitreal injections of Volociximab ( $\alpha 5\beta 1$  integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (2010-2011)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Ophthotech OPH2001**, “A Phase I study to establish the safety and tolerability of ARC1905 (ANTI-C5 APTAMER) in subjects with Dry Age-Related Macular Degeneration.” (2009-2011)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Victor Gonzales, M.D., PRESERVE**, “Pegaptanib for Retinal Edema Secondary to DiabeticVascular Disease.” (2010-2011)

Primary Investigator: Sunil S. Patel M.D., PhD

Sub-Investigator: S. Young Lee, M.D., Grant P. Janzen, M.D.

**Allergan 190342-032D-01**, “A Multicenter, Masked, Randomized, Sham-controlled, Paired-eyed Comparison, 12-Month (Plus 12-Month Extension) Study to Evaluate the Safety and Effects on Retinal structure and Visual Function of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator system in Patients with Geographical Atrophy from Age-Related Macular Degeneration.” (2008-2011)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Regeneron VGFT-OD-0605**, “A randomized, double masked, active controlled Phase III study of the efficacy, safety, and tolerability of repeated doses of intravitreal VEGF Trap in subjects with Neovascular Age-Related Macular Degeneration.” (2007-2011)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Alimera Sciences C01-05-001**, “A randomized, double-masked, parallel group, multicenter, dose-finding comparison of the safety and efficacy of ASI-001A 0.5  $\mu$ g/day and ASI-001B 0.2  $\mu$ g/day Fluocinolone Acetonide intravitreal inserts to sham injection in subjects with diabetic macular edema.” (2006-2011)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee M.D.

**Allergan 190342-031D-01**, “A Multicenter, Masked, Randomized, Sham Controlled, Parallel-group, 3-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in improving Visual Function in patients with a previous Rhegmatogenous Macular-Off Retinal Detachment.” (2009-2011)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Alcon C-09-023 (Waltz)**, “A dose-escalated study of AL-39324 Suspension versus Lucentis® for the treatment of Exudative Age Related Macular Degeneration.” (2009-2011)

Primary Investigator: Sunil S. Patel M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Regeneron VGFT-OD-0706**, “A Double-Masked, Randomized, Controlled study of the safety and efficacy, Tolerability and Biological effect of repeated Intravitreal Administration of VEGF-Trap in patients with Diabetic Macular Edema (DME).” (2009-2010)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Genentech FVF3426g HORIZON**, “An open-label, Multicenter extension study to evaluate the safety and tolerability of Ranibizumab in subjects with Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) who have completed a Genentech-sponsored Ranibizumab study.” (2008-2010)

Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.

**Ophthotech OPH3000**, “A phase I ascending dose and parallel group trial to establish the safety, tolerability and pharmacokinetics profile of multiple intravitreal injections of Volociximab ( $\alpha 5\beta 1$  integrin antagonist as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (2008-2010)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Ophthotech OPH2000**, “A Phase I, Ascending Dose and Parallel Group Trial to establish the Safety, Tolerability and Pharmacokinetic Profile of Multiple Intravenous Injections of ARC1905 (ANTI-C5 APTAMER) Given either in combination therapy with multiple doses of Lucentis® 0.5 mg/eye, or with one induction dose of Lucentis® 0.5 mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (2008-2010)

Primary Investigator: Sunil S. Patel, M.D., PhD

Sub-Investigator: S. Young Lee, M.D.

**Allergan 206207-012-00**, “A 52-week, masked, multicenter, randomized, controlled trial (with up to 13 weeks additional follow-up) to assess the safety and efficacy of 700µg Dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema (DME).” (2007-2010)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: Sunil Patel, M.D., Ph.D.

**Ophthotech OPH1000**, “A Phase I, single ascending dose trail to establish the safety, tolerability and pharmacokinetic profile of intravitreal injection of E10030 (Anti-PDGF Pegylated Aptamer) monotherapy and of E10030 given in combination with Lucentis 0.5 Mg/eye in subjects with Neovascular Age-Related Macular Degeneration.” (2007-2010)

Primary Investigator: Sunil S. Patel, M.D., Ph.D.

Sub-Investigator: S. Young Lee, M.D.

**Genentech FVF4165g BRAVO**, “A phase III multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to branch retinal vein occlusion.” (2007-2010)

Primary Investigator: S. Young Lee, M.D.

Sub-Investigator: Sunil S. Patel, M.D., Ph.D.

**Genentech FVF4166g CRUISE**, “A phase III, Multicenter, randomized, sham injection-controlled study of the efficacy and safety of ranibizumab injection compared with sham in subjects with macular edema secondary to central retinal vein occlusion.” (2007-2010)

Primary Investigator: S. Young Lee, M.D.

Sub-Investigator: Sunil S. Patel, MD, PhD.

**Allergan 206207-019**, “A 26-week, Open Label study to assess the safety and efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis® in the treatment of subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.” (2008-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Allergan 206207-018**, “A 26-week, Open-Label study to assess the safety and efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the treatment of Vitrectomized subjects with Diabetic Macular Edema.” (2008-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Allergan SIRIUS**, “A 2-year, Multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN 211745 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.” (2007-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Allergan 206207-016**, “A 6-Month, single- masked, multicenter, randomized, controlled study to assess the safety and efficacy of 700µg Dexamethasone posterior segment drug delivery system applicator system as adjunctive therapy to Lucentis compared with Lucentis alone in the treatment of patients with Choroidal Neovascularization secondary to Age-Related Macular Degeneration.” (2007-2009)

Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.

**Jerini J0642701**, “A Phase I open-label study to investigate the safety, tolerability and pharmacokinetic profile of single and repeated doses of JSM6427 following administration by intravitreal injection in patients with Neovascular Age-Related Macular Degeneration.” (2007-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**OPKO Health ACU301C**, “A Phase 3, Randomized, Double-masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® Monotherapy every four weeks in patients with Exudative Age-Related Macular Degeneration (AMD).” (2007-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Alcon C-06-30**, “The Natural History of Geographical Atrophy Progression (GAP) Secondary to Age-Related Macular Degeneration (AMD).” (2008-2009)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Allergan 206207-009-01**, “A six-month, phase III, multicenter, masked randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700µg and 350µg dexamethasone Posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion.” (2006-2009)

Primary Investigator: S. Young Lee M.D. Sub-Investigator: Sunil Patel, M.D., Ph.D.

**Eyeteck 1023**, “A phase IV, multi-center trial of maintenance intravitreal injections of Macugen® (Pegaptanib Sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with modality resulting in maculopathy improvement.” (2006-2008)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**ALCON C0459**, “Anecortave Acetate 15mg administered every 3 months versus Anecortave Acetate 15mg administered every 6 months versus Anecortave Acetate 30mg administered every 6 months in patients with exudative age-related macular degeneration.” (2005-2008)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.



**Alcon C-05-62**, “A clinical evaluation of the safety and efficacy of preservative-free Triamcinolone Acetonide sterile suspension for visualization during vitreoretinal surgery.” (2007)

Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.

**ALCON C0418**. “Clinical evaluation of the safety of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus for use During Surgery for removal of epimacular membrane and vitrectomy.” (2006-2007)

Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, M.D., Ph.D.

**EYETECH EOP1012**, “A phase 3B/4, randomized, active-controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen given every 6 weeks for up to 102 weeks plus sham Photodynamic Therapy to Macugen plus PDT with Visudyne, in subjects with predominantly classic subfoveal choroidal neovascularization secondary to age-related macular degeneration.” (2005-2007)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**EYETECH EOP1013**, “A phase 2/3, randomized, controlled, double-masked, multi-center, comparative dose-finding trial in parallel groups, to compare the safety and efficacy of intravitreal injections of 0.3, 0.03, 0.003mg Macugen, given as often as every 6 weeks for 3 years, to sham injections, in subjects with Diabetic Macular Edema involving the center of the macula.” (2005-2007)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**DRCR Protocol B**, “A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for DME.” (2004-2007)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Diabetic Retinopathy Clinical Research Network**. “A Randomized Trial Comparing Intravitreal Corticosteroids and Laser Photocoagulation for Diabetic Macular Edema.” (2004-2007)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**The Standard Care vs. Corticosteroid for Retina Vein Occlusion (SCORE) Study**. “Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injections of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion.” (2004-2007)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Eyeteck EOP1011B**. “A Phase II randomized, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO.” (2004-2005)

Primary Investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**Genaera Corporation MSI-1256F-209**. “A Phase 2, multi-center, Randomized, Masked, Controlled Study of the MSI-1256F (Squalamine Lactate) for Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.” (2004-2005)

Primary Investigator: S. Young Lee, M.D. Sub-Investigator: Sunil S. Patel, MD, PhD.

**Alcon: Anecortave Acetate Risk-Reduction Trial (AART) C-02-60**. “Multicenter, double-masked, randomized, parallel groups clinical trial to demonstrate that Anecortave Acetate is safe and effective versus sham in arresting the progression of non-exudative AMD in patients who are at-risk for progressing to exudative AMD.” (2004-2008)

Primary investigator: Sunil S. Patel, M.D., Ph.D. Sub-Investigator: S. Young Lee, M.D.

**VAM study for management of Wet Age Related Macular Degeneration.** *Management of predominantly classic subretinal neovascular membranes with Visudyne.*(1999-2000).

Primary investigator: Sunil S. Patel, M.D., Ph.D.

**Collaborative Ocular Melanoma Study (COMS)** (1996-1997) at Doheny Eye Institute – Management of Choroidal melanoma with radioactive plaque or enucleation. Certified as a plaguing and enucleation surgeon.

## MANUSCRIPTS (Authored)

**Patel, S.S.**, D.L. Thiele, and P.E. Lipsky. 1987. Major histocompatibility complex-unrestricted cytotoxic activity of human T cells. Analysis of precursor frequency and effector phenotype. *J. Immunology*. 139:3886.

Thiele D.L., **S.S. Patel**, and P.E. Lipsky. 1988. Anti-CD3 and phorbol myristate acetate regulation of MHC unrestricted T cell cytotoxicity: Lack of a requirement for CD3/T cell receptor complex expression during tumor lysis. *J. Immunology*. 140:3253.

Davis, L.S., **S.S. Patel**, J.P. Atkinson, and P.E. Lipsky. 1988. Decay-accelerating factor functions as a signal transducing molecule for human T cells. *J. Immunology*. 141:2246.

**Patel, S.S.**, A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1988. Phenotypic and functional characterization of human T cell clones. *J. Immunology*. 141:3726.

Geppert, T.D., M.C. Wacholtz, **S.S. Patel**, E. Lightfoot, and P.E. Lipsky. 1989. Activation of human T cell clones and Jurkat cells by cross-linking class I major histocompatibility complex molecules. *J. Immunol.*142:3763.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. Patterns of co-stimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules. *J. Immunology*. 142:4201.

**Patel, S.S.** 1989. Functional and phenotypic analysis of human T cell clones. University of Texas Southwestern Medical School. Dissertation.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. LFA-1 is a signaling molecule for human T lymphocytes. In *Structure and function of molecules involved in leukocyte adhesion*. Eds. A.S. Rosenthal, T.A. Springer, D.C. Anderson, and R. Rothlein. Springer-Verlag. p.254-264.

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. Leukocyte function-associated antigen 1 is an activation molecule for human T cells. *J. Exp. Med.* 170:431.

**Patel, S.S.**, M.C. Wacholtz, A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1989. Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. *J. Immunology*. 143:1108.

Hirohata, **S.**, **S.S. Patel**, and P.E. Lipsky. 1990. Regulation of human B cell responsiveness by CD8+ T cells: Differential effects of stimulation with monoclonal antibodies to CD3 and pokeweed mitogen. *Cell. Immunology*. 127:35.

**Patel, S.S.**, D.L. Thiele, and P.E. Lipsky. 1993. Stimulus-dependent modulation of human B cell function by T cell clones. *Cell. Immunology*. 146:362.

Jou, J., **S. S. Patel**, C. Yo, A.A. Sadun. 1995. Orbital Coccidioidomycosis presenting as a lacrimal fossa mass. *Brit J. Ophthalmology*. 79:1145.

**Patel, S.S.**, A.R. Rutzen, J.L. Marx, A.B. Thach, L.P. Chong, and N.A. Rao. 1996. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Ophthalmology*. 103:1476.

Marx, J.L., M.A. Kapusta, **S.S. Patel**, F. Walonker, N.A. Rao, and L.P. Chong. 1996. Use of the ganciclovir implant in the treatment of recurrent CMV retinitis. *Archives of Ophthalmology*. 114:815.

Johnston, R.H., R.L. Nguyen, A. Jongsareejit, B.R. Lee, **S. Patel**, and L. Chong. 1999. Clinical Study of combined penetrating keratoplasty, pars plana vitrectomy with temporary keratoprosthesis, and pars plana seton implant. *Retina* 19:116.

## MANUSCRIPTS (Clinical Trials)

Collaborative Ocular Melanoma Study Group: The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma, III: Initial mortality findings. COMS Report No. 18. *Archives of Ophthalmology*. (2001)119:969.

Collaborative Ocular Melanoma Study Group: The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Archives of Ophthalmology*. (2001)119:951.

Collaborative Ocular Melanoma Study Group: Collaborative Ocular Melanoma Study (COMS). Randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual Acuity after 3 years. COMS Report No.16. *Ophthalmology*. (2001)108:348.

Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS Report No. 15. *Archives of Ophthalmology*. (2001)119:670.

SCORE Study Group, Bhavsar, AR, et al. The risk of Endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. *Am J Ophthalmol*. (2007) 144:454-456.

SCORE Research Group, Scott, IU, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. *Arch Ophthalmol*. (2009)127:1115-28.

SCORE Study Research Group, Ip, MS. et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5. *Arch Ophthalmol*.(2009) 127:1101-14.

SCORE Study Investigator Group, Scott, IU, et al. SCORE Study Report 7: Incidence of intravitreal silicone oil droplets associated with staked-on vs. lure cone syringe design. *Am J Ophthalmol*. (2009)148:725-732.

DRCR:Sun JK, Aiello LP, Stockman M, Cavallerano JD, Kopple A, Eagan S, Qin H, Kollman C, Beck RW, Glassman AR; Diabetic Retinopathy Clinical Research Network. Effects of dilation on Electronic-ETDRS Visual Acuity in diabetic patients. *Invest Ophthalmol Vis Sci*. (2009) 50:1580-4.

DRCR:Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina*.2008 Jan;28(1):36-40.

DRCR:Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology*.2007 Oct;114(10):1860-7.

Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C. Three-year follow up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. *Arch Ophthalmol.* 2009 Mar;127(3):245-51.

Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetate and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology.* 2008 Sep;115(9):1447-9.e1-10.

DRCR: Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H; Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. *Retina.* 2008 Jul-Aug;28(7):919-30.

DRCR: Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris FL, Glassman AR, Ip MS, Miller KM, for the Diabetic Retinopathy Clinical Research Network. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. *Ophthalmology* 2010 May;117:946-953.

Level Study Group, Friberg, TR, et al. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. 2010. *Br J Ophthalmol.* (in press)

## ABSTRACTS

Kermani-Arab, V., **S.S. Patel**, J.L. Fahey, and A. Razzaque Ahmed. 1983. Interleukin 2 deficiency in pemphigus. *Clinical Research* 31:578A.

**Patel, S.S.**, D.L. Thiele, and P.E. Lipsky. 1987. Nonspecific cytotoxic potential of cloned human Lymphocytes. *Fed. Proc.* 46:476 (#931).

Parkey, R.T., D.L. Thiele, **S.S. Patel**, and P.E. Lipsky. 1988. Lack of a requirement for CD3/T cell receptor complex recognition in mediation of MHC-unrestricted cytotoxicity by activated T cells. *FASEB J.* 2:A463 (#975).

**Patel, S.S.**, D.L. Thiele, and P.E. Lipsky. 1988. Human peripheral blood T cell clones exhibit multiple functional activities. *FASEB J.* 2:A476 (#1047).

Ritter, A.R., L.S. Davis, **S.S. Patel**, J.P. Atkinson, and P.E. Lipsky. 1988. An antiserum to decay-accelerating factor (DAF) activates human T cells. *FASEB J.* 2:A871 (#3347).

Geppert, T.D., M.C. Wacholtz, **S.S. Patel**, E. Lightfoot, and P.E. Lipsky. 1988. T cell activation by cross-linking class I major histocompatibility complex (MHC) molecules. *FASEB J.* 2:A1655 (#7888).

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1988. Cross-linking class I major histocompatibility complex (MHC) determinants stimulate human CD4+ and CD8+ T cell clones. *FASEB J.* 2:A1828 (#8897).

Thiele, D.L., **S.S. Patel**, and P.E. Lipsky. 1988. Anti-CD3 mediated regulation of MHC-unrestricted cytotoxicity by activated T cells: Lack of role for CD3/T cell receptor complex in tumor lysis. *Clinical Research* 36:449A.

**Wacholtz, M.C., S.S. Patel, and P.E. Lipsky.** 1989. LFA-1 as a signaling molecule. *Clinical Research.* 37:560A.

**Patel, S.S.**, A.D. Duby, D.L. Thiele, and P.E. Lipsky. 1989. Functional characterization of human peripheral blood CD3+CD4-CD8- and CD3+CD4+CD8+ T cell clones. *FASEB J.* 3:A515 (#1681).

Wacholtz, M.C., **S.S. Patel**, and P.E. Lipsky. 1989. LFA-1 (CD11a/CD18) as a signaling molecule in T cell activation. *FASEB J.*3:A786 (#3349).

Kavanaugh, A., **S.S. Patel**, E. Lightfoot, P.E. Lipsky, and N. Oppenheimer-Marks. 1990. Delineation of the capacity of CD18 deficient T cells to bind to and migrate through endothelial cells. *FASEB J.* 4:A2054 (#2092).

**Patel, S.S.**, B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation. *Amer. Acad. of Ophthalmology.*

**Patel, S.S.**, A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Amer. Acad. Of Ophthalmology.*

**Patel, S.S.**, A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Amer. Uveitis Society.*

**Patel, S.S.**, N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. 1996. Initial clinical experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. *ARVO.* S257 (#1173).

Ge, N., **S. Patel**, D. Heuer, D. Minckler, and R. Varma. 1996. Initial clinical experience with the Ahmed glaucoma valve implant in the management of complicated glaucoma. *ARVO.*S258(#1179).

Kapusta, M., J.L. Marx, **S.S. Patel**, N.A. Rao, and L.P. Chong. 1996. The clinical outcome of high dose intravitreal ganciclovir in progressive outer retinal necrosis. *ARVO.* S371(#1716).

Marx, J.L., M.A. Kapusta, **S.S. Patel**, F. Walonker, N.A. Rao, and L.P. Chong. 1996. The use of the ganciclovir implant in the treatment of recurrent CMV retinitis. *ARVO.* S669 (#3072).

Johnston, R.H., P. Lee, **S. Patel**, M. Kapusta, D.A. Frambach, and L.P. Chong. 1997. Management of neovascular glaucoma using combined pars plana vitrectomy and seton implant. *ARVO.*S769. (#3557).

Kapusta, M.A., R.L. Nguyen, R. Johnston, **S. Patel**, P. Lee, and L. Chong. 1997. Is a combined procedure of penetrating keratoplasty, vitrectomy, and seton implant in the pars plana effective? *ARVO.* S666(#3123).

**Patel, S.S.** and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. *AAO.*

**Patel, S.S.**, R. Anand, D. Callanan, and R. Leonard. 1999. Diabetic tractional retinal detachment: Anatomic and functional variables important in visual prognosis. *AAO.*

**Patel, S.S.** and S.Y. Lee. NAION. *AAO* 2006

**Patel, S.S.**, and CRVO study. *ARVO*2007

## INVITED LECTURES

**Patel, S.S.**, B.F. Jost, and G.E. Fish. 1992. Peripapillary choroidal neovascularization: laser treatment versus observation. *Amer. Acad. of Ophthalmology.*

**Patel, S.S.**, A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. *Amer. Acad. Of Ophthalmology.*

**Patel, S.S.,** A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Amer. Uveitis Society.

**Patel, S.S.** 1996. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency syndrome. Vanderbilt University Invited Lecture.

**Patel, S.S.** 1997. Ocular manifestations of the cytomegalovirus infection in patients with acquired immune deficiency syndrome. University of Arkansas Invited Lecture.

**Patel, S.S.** 1998. Current management strategies for CMV retinitis. Southern Retinal Study Group. New Orleans, LA.

**Patel, S.S.** 1998. Evolution of macular hole surgery. Texas Tech University Alumni Lecture.

**Patel, S.S.** 1998. Evolution of macular hole surgery. Vanderbilt University Invited Lecture.

**Patel, S.S.** and R. Anand. 1998. A system for classifying diabetic tractional retinal detachments. Amer. Acad. of Ophthalmology

**Patel, SS** and S Y. Lee. 2006. AAO. NAION.

## PRESENTATIONS

**Patel, S.S.,** B.F. Jost, and G.E. Fish. Peripapillary choroidal neovascularization: laser treatment versus observation. Doheny Alumni Day 1993.

**Patel, S.S.,** R. Kruger, and R. Green. Are two intraocular lenses better than one? Doheny Alumni Day 1994.

**Patel, S.S.,** A.R. Rutzen, J.L. Marx, A.B. Thach, L.P.Chong, and N.A. Rao. 1995. Cytomegalovirus papillitis in patients with acquired immunodeficiency syndrome. I. Visual prognosis of patients treated with ganciclovir and/or foscarnet. Doheny Alumni Day 1994.

**Patel, S.S.,** N. Ge, R. Varma, P. Chen, D.K. Heuer, P. Lee, M. Dacey, A. Phillips, and D. Minckler. Initial clinical experience with the Ahmed glaucoma valve in the management of neovascular glaucoma. Doheny Alumni Day 1996.

## COURSES

**Patel, S. S.,** R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments. AAO (1998).

**Patel, S. S.,** R. Anand, D. Callanan, and W. Hutton. Surgical management of diabetic tractional retinal detachments. AAO (1999).

**Patel, S. S.,** R. Anand, D. Callanan, and R. Leonard. Surgical management of diabetic tractional retinal detachments. AAO (2000).